Clinical trial
Bevacizumab, Sorafenib Tosylate, and Temsirolimus in Treating Patients With…
NCT00378703 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00378703 |
|---|---|
| Title | Bevacizumab, Sorafenib Tosylate, and Temsirolimus in Treating Patients With Metastatic Kidney Cancer |
| Official title | The BeST Trial: A Randomized Phase II Study of VEGF, RAF Kinase, and mTOR Combination Targeted Therapy (CTT) With Bevacizumab, Sorafenib, and Temsirolimus in Advanced Renal Cell Carcinoma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v7 |
| Intervention type | Biological, Drug, Other |
| Interventions | Bevacizumab, Laboratory Biomarker Analysis, Pharmacological Study, Sorafenib Tosylate, Temsirolimus |
| Enrollment | 361 |
| Start date | Sep 14, 2007 |
| Primary completion | Feb 7, 2014 |
| Completion | Mar 21, 2017 |
| First posted | Sep 21, 2006 |
| Last update posted | Nov 14, 2018 |
| Countries | Peru, United States |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: